Keyphrases
Neoadjuvant
100%
Phase II Study
100%
Borderline Resectable Pancreatic Cancer
100%
Gemcitabine Plus Nab-paclitaxel
100%
Clinical Trial Registry
50%
Phase II Trial
25%
Irradiation
25%
Adverse Events
25%
Postoperative Complications
25%
Pneumonia
25%
Esophageal Cancer
25%
Median Overall Survival
25%
Overall Survival Time
25%
2-cycles
25%
Pancreatectomy
25%
Recurrence-free Survival
25%
Disease Progression
25%
Resectable Pancreatic Cancer
25%
Safe Treatment
25%
Overall Rate
25%
Gemcitabine
25%
Treatment Regimen
25%
Promising Treatment
25%
Neoadjuvant Therapy
25%
Survival Data
25%
R0 Resection Rate
25%
Resection Rate
25%
Clavien-Dindo Classification
25%
Nab-paclitaxel
25%
Interstitial Lung Disease
25%
History of Radiation Therapy
25%
One-cycle
25%
Prospective Evaluation
25%
Medicine and Dentistry
Paclitaxel
100%
Pancreas Cancer
100%
Arm
100%
Gemcitabine
100%
Surgery
40%
Overall Survival
40%
Clinical Trial
40%
Pancreatectomy
20%
Radiation Therapy
20%
Adverse Event
20%
Postoperative Complication
20%
Esophageal Cancer
20%
Survival Time
20%
Recurrence Free Survival
20%
Disease Exacerbation
20%
Neoadjuvant Therapy
20%
Phase II Trials
20%
Interstitial Lung Disease
20%
Pharmacology, Toxicology and Pharmaceutical Science
Paclitaxel
100%
Pancreas Cancer
100%
Gemcitabine
100%
Overall Survival
40%
Clinical Trial
40%
Adverse Event
20%
Survival Time
20%
Recurrence Free Survival
20%
Disease Exacerbation
20%
Phase II Trials
20%
Esophagus Cancer
20%
Postoperative Complication
20%
Interstitial Lung Disease
20%
Biochemistry, Genetics and Molecular Biology
Gemcitabine
100%
Overall Survival
50%
Clinical Trial
50%
Survival Time
25%
Recurrence Free Survival
25%
Phase II Trials
25%